Compare CIG & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIG | TFX |
|---|---|---|
| Founded | 1952 | 1943 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.4B |
| IPO Year | N/A | N/A |
| Metric | CIG | TFX |
|---|---|---|
| Price | $2.00 | $104.72 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $139.88 |
| AVG Volume (30 Days) | ★ 3.4M | 797.5K |
| Earning Date | 03-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 13.09% | 1.32% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $7,960,960,695.00 | $3,189,988,000.00 |
| Revenue This Year | N/A | $9.90 |
| Revenue Next Year | N/A | $10.51 |
| P/E Ratio | $8.36 | ★ N/A |
| Revenue Growth | ★ 9.92 | 5.42 |
| 52 Week Low | $1.59 | $102.58 |
| 52 Week High | $2.30 | $185.94 |
| Indicator | CIG | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 32.01 |
| Support Level | $1.95 | $108.39 |
| Resistance Level | $2.04 | $127.49 |
| Average True Range (ATR) | 0.04 | 3.45 |
| MACD | -0.00 | -2.41 |
| Stochastic Oscillator | 32.14 | 8.22 |
Cia Energetica DE Minas Gerais - Cemig, formerly Energy Company of Minas Gerais, is a Brazilian power company that generates, transmits, and distributes electricity. As one of the power companies in Brazil, the firm operates across Brazilian states and Chile. The company has various subsidiaries and operates chiefly through its generation, transmission, distribution, and gas segments. The majority of the company's revenue is derived from electricity sales to consumers. The company generates power through hydroelectric resources and, secondarily, through thermal and wind resources.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.